Malecare Prostate Cancer Support Group

Malecare

About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Early Use of Zoledronic Acid (Zometa) in Men with Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).

We have long known that Zoledronic Acid (Zometa) decreases a man’s risk of developing skeletal-related events (SREs) in men with castration-resistant advanced prostate cancer (CRPC) and bone metastases. In a phase III study that evaluated efficacy and safety of earlier treatment with Zometa in men with advanced prostate cancer which is still castration-sensitive found that [...]

By |2017-10-19T10:50:06-04:00March 12th, 2013|Advanced Prostate Cancer, bisphosphonates, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Zometa|0 Comments
Read More

Our Right To Die – An Unfair Media Circus that Never Should Have Happened

Today, I am going to make a little change in my post. Instead of discussing additional ASCO Conference abstracts of interest to men with advanced prostate cancer (I will come back to them in short order), I want to respond to the latest public outrage that has been in the media. A recent story has [...]

By |2017-10-19T10:50:08-04:00March 8th, 2013|Advanced Prostate Cancer, How We Live, Uncategorized, Understanding APC|4 Comments
Read More

From ASCO 2013 – Updated Analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) from the phase III randomized trial (ALSYMPCA).

Ra-223 (Alpharadin)is an alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range (< 100 ?m) alpha-particles. Currently it has been submitted to the FDA for approval, which we hope will happen by August 2013. In the phase 3, double-blind, randomized, multinational ALSYMPCA study, Ra-223 significantly improved overall survival (OS) in men with castrate resistant advanced prostate [...]

By |2017-10-19T10:50:08-04:00March 4th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments
Read More

FROM THE 2013 ASCO GU CONFERENCE –CHEMOTHERAPY AND THE USE ANTICOAGULANTS INCREASE PROSTATE CANCER SURVIVAL RATES

Another interesting research abstract presented at the Genitourinary Cancers Symposium in Orlando Florida this month found that men with prostate cancer who were on chemotherapy who had also received anticoagulant (blood-thinners) medications experienced improved overall survival rates compared to men who did not take anticoagulants drugs. This retrospective study involved the reviewed of the medical [...]

By |2013-03-03T14:47:03-05:00March 3rd, 2013|Advanced Prostate Cancer, ASCO, Chemo Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC|1 Comment
Read More

More From the 2013 ASCO GU Conference – An Updated Analysis of the Phase III Randomized Trial (ALSYMPCA) of Radium-223 dichloride (Ra-223)

Ra-223 is an investigational alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range alpha-particles. The recently completed phase 3, double-blind, randomized, multinational ALSYMPCA study showed that Ra-223 significantly improved over all survival (OS) in CRPC men with bone mets by a median increase of 3.6 months compared with placebo (median OS: 14.9 vs 11.3 mo; P [...]

By |2017-10-19T10:50:08-04:00February 28th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized|0 Comments
Read More
Go to Top